ClinicalTrials.gg
Sign In
Drug

Tislelizumab clinical trials

Also written BGB-A317 and Tevimbra.

studies test it
434
open now
239
in phase 3
45
first study started
2015

How each study uses tislelizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tislelizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Mar 2024 · TEVIMBRA · BLA 761232 (FDA, Drugs@FDA)
European Union
15 Sept 2023 · Tevimbra · EMEA/H/C/005919 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tislelizumab
268
Tislelizumab Injection
8
Cisplatin
6
Tirelizumab
6
Carboplatin
5

Brand

Tevimbra
18

Development codes

BGB-A317
72
VDT482
1

In one entry with another drug

Given together, or one or the other

Tislelizumab plus Bevacizumab
4
Tislelizumab, Lenvatinib
2
Tislelizumab, Carboplatin, Pemetrexed
2
RC48 Combined With Tislelizumab
2
Tislelizumab combined with Lenvatinib
2
Donafenib + Tislelizumab
2
Tislelizumab, paclitaxel, Carboplatin
2
HAIC + Tislelizumab +lenvatinib
2

Studies by the year they started

434 studies that test it; most in 2022 (82)

Studies that test tislelizumab, by start year
YearStudies
20151
20163
20175
201811
20198
202031
202164
202282
202373
202458
202563
202635

By phase

A phase 1/2 study counts in both.

Early Phase 1
4
Phase 1
65
Phase 2
340
Phase 3
45
Phase 4
11
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
36
Carcinoma, Hepatocellular
31
Esophageal Squamous Cell Carcinoma
21
Stomach Neoplasms
19
Colorectal Neoplasms
18
Squamous Cell Carcinoma of Head and Neck
12
Triple Negative Breast Neoplasms
11
Cholangiocarcinoma
11
Esophageal Neoplasms
10
Small Cell Lung Carcinoma
9
Rectal Neoplasms
9
Nasopharyngeal Carcinoma
8

Who runs them

Industry 73 · Other 361

BeiGene (48) · Fudan University (33) · Sun Yat-sen University (20) · Tianjin Medical University Cancer Institute and Hospital (16) · Fujian Cancer Hospital (15) · Shanghai Zhongshan Hospital (9) · The First Affiliated Hospital with Nanjing Medical University (8) · Zhejiang Cancer Hospital (7)

Often tested with

Tested in the same studies.

Lenvatinib (29) · Paclitaxel (20) · HMPL-013 (15) · Anlotinib (14) · Sitravatinib (12) · Albumin-Bound Paclitaxel (12) · Cisplatin (12) · Disitamab vedotin (10)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 16 phase 3 studies under way

Tislelizumab is the comparator. A study of two new drugs counts under both.

  • 2Anti-EGFR Antibody-drug Conjugate CPO301 · CSPC Megalith Biopharmaceutical Co.,Ltd. · next primary completion Sep 2027
  • 2Enlonstobart · CSPC Megalith Biopharmaceutical Co.,Ltd. · next primary completion Sep 2027
  • 2RC148 · RemeGen Co., Ltd. · next primary completion Dec 2027
  • 1Trastuzumab rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Feb 2031
  • 1Adebrelimab · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Feb 2031
  • 1Ifebemtinib · Shanghai Jeyou Pharmaceutical Co., Ltd. · next primary completion Apr 2029
  • 1Pemetrexed · Jiangsu Hansoh Pharmaceutical Co., Ltd. · next primary completion May 2030
  • 1SYHX2011 · Shanghai Chest Hospital · next primary completion Dec 2027
Reaching primary completion within a year · 58, 10 in phase 3

Studies that test tislelizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses tislelizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 434

See all 434 studies that test tislelizumab →

Given beside what is tested · 142 — tislelizumab is usual care or a partner of the new treatment

Showing 20 of 142.

As the comparator · 19 — what is tested is compared with tislelizumab

Codes

What other systems call tislelizumab · ClinicalTrials.gg INT001346

  • MeSH (NLM) C000707970tislelizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 0KVO411B3NTISLELIZUMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q28209583tislelizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C121775TislelizumabOne source FDA
  • DrugBank DB14922One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.